MENU
+Compare
VRNA
Stock ticker: NASDAQ
AS OF
Jun 4, 04:59 PM (EDT)
Price
$84.05
Change
-$0.76 (-0.90%)
Capitalization
7.15B

VRNA Verona Pharma plc Forecast, Technical & Fundamental Analysis

Verona Pharma PLC is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs... Show more

VRNA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for VRNA with price predictions
Jun 04, 2025

VRNA in upward trend: 10-day moving average broke above 50-day moving average on April 29, 2025

The 10-day moving average for VRNA crossed bullishly above the 50-day moving average on April 29, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on May 19, 2025. You may want to consider a long position or call options on VRNA as a result. In of 94 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for VRNA just turned positive on May 19, 2025. Looking at past instances where VRNA's MACD turned positive, the stock continued to rise in of 43 cases over the following month. The odds of a continued upward trend are .

VRNA moved above its 50-day moving average on May 12, 2025 date and that indicates a change from a downward trend to an upward trend.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where VRNA advanced for three days, in of 293 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 199 cases where VRNA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 11 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where VRNA declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

VRNA broke above its upper Bollinger Band on May 30, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock better than average.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. VRNA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (31.546) is normal, around the industry mean (16.306). P/E Ratio (0.000) is within average values for comparable stocks, (59.921). VRNA's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.224). Dividend Yield (0.000) settles around the average of (0.040) among similar stocks. P/S Ratio (58.480) is also within normal values, averaging (265.014).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

View a ticker or compare two or three
VRNA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

VRNA is expected to report earnings to rise 119.00% to -4 cents per share on July 31

Verona Pharma plc VRNA Stock Earnings Reports
Q2'25
Est.
$-0.04
Q1'25
Beat
by $0.05
Q4'24
Beat
by $0.02
Q3'24
Est.
$-0.07
Q2'24
Missed
by $0.06
The last earnings report on April 29 showed earnings per share of -1 cents, beating the estimate of -7 cents. With 1.32M shares outstanding, the current market capitalization sits at 7.15B.
A.I. Advisor
published General Information

General Information

a r&d company for the treatment of allergic rhinitis and other chronic respiratory diseases

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Pharmaceuticals Other
Address
3 More London Riverside
Phone
+44 2032834200
Employees
79
Web
https://www.veronapharma.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
RHRX15.870.13
+0.80%
RH Tactical Rotation ETF
RSST22.310.10
+0.45%
Return Stacked® US Stocks & Mgd Futs ETF
VUSB49.650.04
+0.08%
Vanguard Ultra-Short Bond ETF
PSMD29.77N/A
-0.02%
Pacer Swan SOS Moderate (January) ETF
CLOZ26.63-0.08
-0.30%
Eldridge BBB-B CLO ETF

VRNA and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, VRNA has been loosely correlated with COGT. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if VRNA jumps, then COGT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To VRNA
1D Price
Change %
VRNA100%
-0.98%
COGT - VRNA
39%
Loosely correlated
-2.59%
ROIV - VRNA
39%
Loosely correlated
-0.31%
TRDA - VRNA
39%
Loosely correlated
-3.76%
ZYME - VRNA
39%
Loosely correlated
+0.99%
CRNX - VRNA
39%
Loosely correlated
+0.78%
More